Lucia B. Jilaveanu
Yale Cancer Center(US)Yale University(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Brain Metastases and Treatment
Most-Cited Works
- → Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial(2016)990 cited
- → Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial(2020)530 cited
- → Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial(2018)276 cited
- → KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements(2021)248 cited
- → Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites(2015)201 cited
- → PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors(2017)155 cited
- → PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases(2014)153 cited
- → A phase 2 trial of dasatinib in advanced melanoma(2010)151 cited
- → Melanoma central nervous system metastases: current approaches, challenges, and opportunities(2016)144 cited
- → Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment(2016)132 cited